Eikon Therapeutics, Inc. · NASDAQ:EIKN
Eikon Therapeutics — Corporate Update (November 2026)
56 slides from Eikon Therapeutics's corporate update, November 2026
Slide 1: Q4 Company Update
Q4 Company Update November 2026 © 2026 | 1
Slide 2: Disclaimer
Disclaimer Any statements made in this presentation that are not statements of historical fact, including statements about our beliefs and expectations, are forward-looking statements and should be evaluated as such. Forward-looking statements include information concerning the strategy, initiation,
Slide 3: Eikon is building a next-generation biopharmaceutical company
Eikon is building a next-generation biopharmaceutical company. We have a late-stage clinical pipeline with multiple registration-enabling studies, a growing portfolio of earlier clinical stage programs, and a productive discovery platform advancing novel drug candidates into the clinic. Non-confiden
Slide 4: Eikon Therapeutics Investment Highlights
Eikon Therapeutics Investment Highlights Clinical-stage pipeline, multiple opportunities including TLR7/8 and PARP1 franchise Built by the team behind dozens of industry-leading medicines including Keytruda® Proprietary SMT discovery platform developing assets for the clinic Multiple anticipated cat
Slide 5: Eikon's pipeline includes multiple indications addressing significant unmet medical needs
Eikon’s pipeline includes multiple indications addressing significant unmet medical needs Candidate/ Target Program Target Indication(s) Pre-Clinical Phase 1 Phase 2 Phase 3 Ownership TeLuRide-006 Melanoma1 EIK1001 TLR7/8 TeLuRide-005 enrollment completed Global exclusive NSCLC2 license TeLuRide-008
Slide 6: Executive Summary
Executive Summary © 2026 | 6
Slide 7: KEYNOTE studies established standard-of-care in non-small cell lung cancer
KEYNOTE studies of pembrolizumab + chemotherapy vs chemotherapy alone established the standard-of-care in non-small cell lung cancer Investigator-based assessment from established standard of care Trial Regimen N ORR DCR DOR (months) Median: KEYNOTE 189 (Non-Squamous) Pembro + 12.6 chemo 43% 81% vs.
Slide 8: TeLuRide-005: EIK1001 activity in combination with Keytruda plus chemotherapy in NSCLC
TeLuRide-005: Evidence that addition of EIK1001 has activity in combination with Keytruda plus chemotherapy in NSCLC Squamous N = 29* | 33 SQ (Efficacy Evaluable | Total) % ORR‡ (CR+PR) 72% Median Duration of Response: 12.9 months DCR (CR+PR+SD) 100% Median DOR (months) 12.9 Note: Investigator-based
Slide 9: EIK1003 Cohort 1C: PARPi combination with full-dose paclitaxel
EIK1003 Cohort 1C provides first demonstration of successful PARPi combination with full-dose paclitaxel Response Rate by Tumor Type Tumor type (CR+PR)/Evaluable ORR EIK1003 Cohort 1C Combination with Paclitaxel - Target Lesion Waterfall All tumors 14/53 26.4% Ovarian 8/27 29.6% Breast 6/26 23.1% Be
Slide 10: EIK1003 Cohort 1B responses with abiraterone and low rate of anemia
EIK1003 Cohort 1B has encouraging responses in combination with abiraterone and low rate of anemia EIK1003 + Abiraterone Best Overall Response EIK1003 + ARPI Non-Selective Abiraterone Monotherapy PARPi + ARPI DL1-EIK1003 Anaemia Best (% ) Change from Baseline DL2-EIK1003 DL3-EIK1003 (Grade ≥3) 15%*
Slide 11: EIK1004 anti-tumor activity with low rates of grade ≥3 hematological toxicity
EIK1004 exhibits anti-tumor activity across tumor types with low rates of grade ≥ 3 hematological toxicity EIK1004 Best Overall Response ORR‡ DCR 12.1% 62.1% (7/58) (36/58) Best (% ) Change from Baseline ‡Includes confirmed and unconfirmed responses; *Efficacy evaluable patients: 58 EIK1004 Grade ≥
Slide 12: EIK1005: WRN helicase inhibitor safety profile and early clinical activity
EIK1005: Novel WRN helicase inhibitor exhibits a favorable safety profile and early signs of clinical activity EIK1005 Time on Study by Dose (Part A Monotherapy) An early look at the data: EIK1005 monotherapy (n=10 participants) CC Safety Efficacy DLTs – 0 6/10 SD CC TEAE – 90% Participants CC (majo
Slide 13: Eikon expects to deliver key milestones in 2027
Eikon expects to deliver key milestones in 2027 2027 Milestones • TeLuRide-006 – Melanoma: Second interim analysis (IA2) – Analysis to advance Phase 3 development (1H 2027) EIK1001 (TLR 7/8) • TeLuRide-008 – NSCLC: First interim analysis (IA1) – Dose selection for single investigational agent arm (2
Slide 14: Detailed Program Overviews
Detailed Program Overviews © 2026 | 14
Slide 15: EIK1001 – TLR7/8 Dual-Agonist
EIK1001 – TLR7/8 Dual-Agonist © 2026 | 15
Slide 16: EIK1001 potential to enhance the checkpoint therapy market
EIK1001 has the potential to enhance a multi-billion-dollar checkpoint therapy market that has transformed oncology treatment • PD-(L)1 antagonist therapies have transformed oncology • Significant unmet need remains for agents that deepen and extend responses to checkpoint inhibitors • EIK1001 is de
Slide 17: EIK1001: TLR7/8 dual-agonist enhances antigen processing and presentation
EIK1001: Eikon’s TLR7/8 dual-agonist acts systemically to enhance antigen processing and presentation TLR7 and TLR8 activate innate and adaptive anti-tumor immunity l TLR7/8 dual-agonist: Activates both innate and adaptive immune responses l Orthogonal mechanism: To enhance checkpoint inhibition, an
Slide 18: KEYNOTE studies established standard-of-care in non-small cell lung cancer
KEYNOTE studies of pembrolizumab + chemotherapy vs chemotherapy alone established the standard-of-care in non-small cell lung cancer Investigator-based assessment from established standard of care Trial Regimen N ORR DCR DOR (months) Median: KEYNOTE 189 (Non-Squamous) Pembro + 12.6 chemo 43% 81% vs.
Slide 19: TeLuRide-005: well-tolerated with anti-tumor activity (pooled data)
TeLuRide-005: EIK1001 in combination with standard-of-care treatment was well-tolerated and anti-tumor activity observed(pooled data) TeLuRide-005 - Phase 2 Single Arm Data EIK1001 + Pembro + Chemo (Investigator-based assessment) Pooled Results (Squamous & Non-squamous) Response by PD-L1, TPS ORR DC
Slide 20: TeLuRide-005: EIK1001 generally well tolerated, outpatient administration
TeLuRide-005: EIK1001 is observed to be generally well tolerated, permitting administration in out-patient setting Overall Safety Summary Grade ≥ 3 TRAE Occurring in ≥ 2 Subjects NSQ N=39 SQ N=33 All N=72 TEAEs: N % Grade ≥ 3 TRAEs: N(%) N(%) N(%) Any TEAE 72 100% Neutropenia* 13(33.3%) 9(27.3%) 22(
Slide 21: High response rates and durable responses in squamous NSCLC
Encouraging antitumor activity with high response rates and durable responses in squamous NSCLC Phase 2 Single Arm Data (Investigator-based assessment) EIK1001 + Pembro + Chemo SQ Squamous N = 29* ORR‡ (CR+PR) 72% DCR (CR+PR+SD) 100% Median DOR (months) 12.9 ‡Includes confirmed and unconfirmed respo
Slide 22: Deep tumor shrinkage for EIK1001+Pembro+Chemo in squamous NSCLC
Encouraging response rates with deep (>50%) tumor shrinkage observed for EIK1001+Pembro+Chemo in squamous NSCLC EIK1001 Squamous Target Lesion Waterfall Best (%) Change from Baseline Participants Responses are based on RECIST 1.1 Efficacy data as of Oct 1, 2026; safety, exposure, and disposition dat
Slide 23: Durable responses in squamous NSCLC, median DOR 12.9 months
Durable tumor responses in squamous NSCLC observed with a median duration of response of 12.9 months EIK1001 Squamous Time on Study Participants Median Duration of Response: 12.9 months Time Since Initiation of Treatment (months) Responses are based on RECIST 1.1 Efficacy data as of Oct 1, 2026; saf
Slide 24: TeLuRide-005 non-squamous results build momentum
TeLuRide-005 non-squamous results continue to build momentum, supporting the case for TLR7/8 dual-agonist Phase 2 Single Arm Data (Investigator-based assessment) EIK1001 + Pembro + Chemo NSQ Non-squamous N = 36* ORR‡ (CR+PR) 56% DCR (CR+PR+SD) 81% Median DOR (months) 11.2 ‡Includes confirmed and unc
Slide 25: Anti-tumor activity in non-squamous NSCLC with deep responses
TeLuRide-005: Anti-tumor activity in non-squamous NSCLC with an encouraging set of deep (>50% tumor shrinkage) responses EIK1001 Non-squamous Target Lesion Waterfall Best (%) Change from Baseline Participants Responses are based on RECIST 1.1 Efficacy data as of Oct 1, 2026; safety data cutoff: July
Slide 26: 11.2 month median duration of response in non-squamous cohort
TeLuRide-005: 11.2 month median duration of response in the non- squamous cohort as of October 1, 2026 EIK1001 Non-squamous Time on Study Participants Median Duration of Response: 11.2 months Time Since Initiation of Treatment (months) Responses are based on RECIST 1.1 Efficacy data as of Oct 1, 202
Slide 27: EIK1001: Registration-enabling studies in melanoma and NSCLC
EIK1001: Registration-enabling studies address overall survival in patients with advanced melanoma or non-small cell lung cancer Currently conducting multiple clinical trials: Milestone(s): • TeLuRide-005 Phase 2 exploratory/tolerability study in NSCLC •✓ 2H 2026 Phase 2 data readout NSQ of triplet
Slide 28: EIK1003/EIK1004: PARP1-Selective Inhibitors for Treatment of Malignancy
EIK1003/EIK1004: PARP1-Selective Inhibitors for Treatment of Malignancy © 2026 | 28
Slide 29: EIK1003: PARP1 selective inhibitor to overcome current limitations
EIK1003: Eikon’s PARP1 selective inhibitor has potential to overcome current limitations and expand usage setting Selective HRRD = Sensitive l PARP1 inhibition and subsequent trapped PARP1 leads to DNA double strand breaks and anti-tumor activity in HR deficient cells l EIK1003 is designed to be hig
Slide 30: Selective PARP1 inhibitor could expand multiple large treatment markets
Selective PARP1 inhibitor could expand multiple large treatment markets currently limited by tolerability concerns with non-selective PARPis Unselective PARPi’s currently address significant disease opportunities in Ovarian, Prostate, Breast and Pancreatic cancer. Significant expansion could be real
Slide 31: EIK1003 with abiraterone: activity and durable responses in prostate cancer
EIK1003 in combination with abiraterone exhibits encouraging antitumor activity and durable responses in metastatic prostate cancer EIK1003 + Abiraterone Best Overall Response EIK1003 + Abiraterone Time on Study by Tumor Type DL1-EIK1003 Best (% ) Change from Baseline DL2-EIK1003 DL3-EIK1003 IDL3-EI
Slide 32: EIK1003 with abiraterone achieved >30% PSA response rate
EIK1003 in combination with abiraterone achieved a >30% response rate for PSA reductions and was active at all dose levels tested EIK1003 + Abiraterone Maximum PSA Response Maximum (% ) Change from Baseline for PSA DL1-EIK1003 DL2-EIK1003 PSA Response Rate DL3-EIK1003 IDL3-EIK1003 12/39 30.8% Prior*
Slide 33: EIK1003 + abiraterone: tolerable safety with limited hematological toxicity
EIK1003 + abiraterone: Tolerable safety profile observed with limited hematological toxicity in heavily pretreated metastatic prostate cancer Non-selective PARP inhibitors (PARPi) cause significant myelosuppression, likely mediated through inhibition of PARP2. This toxicity is not limited to combina
Slide 34: EIK1003 Cohort 1C: full-dose paclitaxel combination with a PARP inhibitor
EIK1003 Cohort 1C: First successful demonstration of combination of full-dose paclitaxel with a PARP inhibitor EIK1003 Cohort 1C Combination with Paclitaxel - Target Lesion Waterfall Response Rate by Tumor Type Tumor type (CR+PR)/Evaluable ORR Best (%) Change from Baseline All tumors 14/53 26.4% Ova
Slide 35: EIK1003 Cohort 1C: Durable responses in second-line therapy
EIK1003 Cohort 1C: Durable responses in second-line therapy EIK1003 Cohort 1C – Time on Study Response Durability DOR (confirmed responders): 6.3 (1.7 to 11.4) months • 2 confirmed responders ongoing DCR (CR+PR+SD): 79.2% (42/53) Participants Median Relative Dose Intensity (RDI) EIK1003 median RDI:
Slide 36: EIK1003 Cohort 1C: responses and safety in combination with paclitaxel
EIK1003 Cohort 1C: Summary of observed responses and safety profile of EIK1003 in combination with paclitaxel Paclitaxel Combo. Key Endpoints Paclitaxel Combo. Safety Summary ‡ (CR+PR)/Evaluable ORR % N (Total = 61) % Total 14/53 26.41% TEAEs: Tumor Type All 61 100% Breast 6/26 23.1% Grade ≥ 3 49 80
Slide 37: EIK1004 anti-tumor activity observed across tumor types
EIK1004 anti-tumor activity observed across tumor types EIK1004 Best Overall Response Best (% ) Change from Baseline ORR‡ DCR 12.1% 62.1% (7/58) (36/58) ‡Includes confirmed and unconfirmed responses; *Efficacy evaluable patients: 58 • 1 confirmed CR • 6 PRs (2 confirmed) Participants Responses are b
Slide 38: EIK1004 anti-tumor activity observed across doses
EIK1004 anti-tumor activity observed across doses EIK1004 Best Overall Response Best (% ) Change from Baseline ORR‡ DCR 12.1% 62.1% (7/58) (36/58) ‡Includes confirmed and unconfirmed responses; *Efficacy evaluable patients: 58 • 1 confirmed CR • 6 PRs (2 confirmed) Participants Responses are based o
Slide 39: EIK1004 durable responses and adherence after disease stabilization
EIK1004 treatment is associated with durable responses and meaningful adherence to treatment after disease stabilization EIK1004 Time on Study by Tumor Type Treatment Duration (months) • Median (95%CI): 2.9(+/-2.4) • 10.3% of patients remain on treatment EIK1004 Responses Participants • ORR‡ (PR+CR)
Slide 40: EIK1004: favorable hematologic tolerability versus non-selective PARP inhibitors
EIK1004: favorable hematologic tolerability observed compared to non- selective PARP inhibitors EIK1004 All Grade TEAEs EIK1004 Grade ≥ 3 TEAEs N (Total = 68) % N (Total = 68) % TEAEs, Participants with: TEAEs, Participants with: Any 67 98.5 any Grade ≥ 3 12 17.6 Nausea 18 26.5 Nausea 2 2.9 Anemia 1
Slide 41: EIK1003 & EIK1004 current program status
EIK1003 & EIK1004 current program status Currently conducting multiple clinical trials: Milestone(s): • EIK1003-001 (Part 1): • Cohort 1A: Monotherapy •✓ 1H 2026 Read out at ASCO 2026 • Cohort 1B: Combo with abiraterone •✓ 2H 2026 Read out • Cohort 1C: Combo with paclitaxel •✓ 1H 2026 Read out at AS
Slide 42: EIK1005: WRN Inhibitor for Treatment of MSI-High Cancers
EIK1005: WRN Inhibitor for Treatment of MSI-High Cancers © 2026 | 42
Slide 43: WRN Therapeutic Landscape and the EIK1005 Difference
WRN Therapeutic Landscape and the EIK1005 Difference Early generation WRN inhibitors EIK1005 l Unmet Need exists for dMMR or MSI-H cancers l WRN helicase inhibitor could potentially that are refractory to PD-(L)1 inhibitors or that leverage synthetic lethality in MSI-H/dMMR relapse after available t
Slide 44: EIK1005: WRN inhibitor for microsatellite instability high cancers
EIK1005: Eikon’s WRN inhibitor for the treatment of microsatellite instability high cancers l MSI-high cancers rely on WRN helicase activity to resolve secondary DNA structures l WRN inhibition blocks DNA repair leading to fragmented DNA and cell death in sensitive cells l Unmet need exists for canc
Slide 45: WRN trapping and degradation upon inhibition revealed by Eikon SMT
WRN trapping and degradation upon inhibition revealed by Eikon SMT slow WRN upon inhibition Shift from fast to slower proteins is quantifiable WRN VCP pro tea so WRN me WRN Findings led to elucidation of key contributors to WRN inhibitor-driven degradation mechanism © 2026 | 45
Slide 46: EIK1005: favorable safety profile and early signs of clinical activity
EIK1005: Novel WRN helicase inhibitor exhibits a favorable safety profile and early signs of clinical activity EIK1005 Time on Study by Dose (Part A Monotherapy) An early look at the data: EIK1005 monotherapy (n=10 participants) CC Safety Efficacy DLTs – 0 6/10 SD CC TEAE – 90% Participants CC (majo
Slide 47: EIK1005 Current Status
EIK1005 Current Status Currently conducting a Phase 1/2 clinical trial: Milestone(s): • EIK1005-002 Phase 1/2 safety, tolerability and preliminary •✓ 1H 2026 First patient dosed efficacy study in advanced solid tumors with or without •✓ 2H 2026 Initial monotherapy readout microsatellite instability,
Slide 48: EIK1006: Next-Generation AR Antagonist
EIK1006: A Multi-Parameter Optimized Next-Generation AR Antagonist © 2026 | 48
Slide 49: AR antagonists current state and Eikon's approach
AR antagonists current state and Eikon’s approach Current ARPI Eikon’s Answer: EIK1006 l Single “lutamide” structural class shared by l EIK1006: non-lutamide AR antagonist novel current AR antagonists (enzalutamide, chemical structure distinct from currently darolutamide, apalutamide) approved thera
Slide 50: EIK1006: Eikon imaging-based discovery in action
EIK1006: Eikon imaging-based discovery in action Ligand ML Models Developed for AR ML Models R2 • SMT-Based Screening permits rapid evolution Caco-2 Permeability 0.77 of chemical series, optimizing across multiple Chrom LogD 0.86 molecular axes simultaneously, and in this way Kinetic Solubility 0.59
Slide 51: Eikon Technology Provides Novel Scientific Insights and Permits Rapid Lead Optimization
Eikon Technology Provides Novel Scientific Insights and Permits Rapid Lead Optimization © 2026 | 51
Slide 52: Single molecule tracking captures real-time dynamics of individual proteins
Single molecule tracking captures the real-time dynamics of individual proteins at scale Fast 10 Diffusion Coefficient (µm2/s) 7.5 5.0 2.5 0.0 Slow Membranes | DNA | Target Protein Non-confidential © 2026 | 52
Slide 53: Eikon's discovery platform designed to accelerate drug discovery
Eikon’s discovery platform is designed to accelerate drug discovery leveraging advanced technologies SINGLE AI/ML-ENHANCED ROBOTICS SYSTEMS MOLECULE DATA ANALYSIS & AUTOMATION BIOLOGY TRACKING © 2026 | 53
Slide 54: Conclusion
4 Conclusion © 2026 | 54
Slide 55: Eikon Therapeutics highlights
Eikon Therapeutics highlights 1 Led by world-renowned drug developers 2 Clinical-stage programs have generated early signs of encouraging clinical activity Internally identified and strategically tailored product candidates advancing into clinical 3 investigation 4 Technology platform, centered arou
Slide 56: © Copyright, All Rights Reserved Eikon Therapeutics 2026
© Copyright, All Rights Reserved Eikon Therapeutics 2026
Eikon Therapeutics — Corporate Update (November 2026) on 6ix